These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24874279)

  • 1. Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: new antiplatelet agents.
    Fuentes E; Palomo I
    Vascul Pharmacol; 2014 Sep; 62(3):162-6. PubMed ID: 24874279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of antiplatelet activity of nifedipine: role of peroxisome proliferator-activated receptor-β-γ-dependent processes.
    Shih CY; Lin MH; Fan HC; Chen FC; Chou TC
    J Hypertens; 2014 Jan; 32(1):181-92. PubMed ID: 24126710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
    Bisgaier CL; Oniciu DC; Srivastava RAK
    J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of the anti-platelet effect of natural bioactive compounds: role of peroxisome proliferator-activated receptors activation.
    Fuentes E; Fuentes F; Palomo I
    Platelets; 2014; 25(7):471-9. PubMed ID: 24246093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P; Fruchart JC; Staels B
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiovascular effects of peroxisome proliferator-activated receptor agonists.
    Friedland SN; Leong A; Filion KB; Genest J; Lega IC; Mottillo S; Poirier P; Reoch J; Eisenberg MJ
    Am J Med; 2012 Feb; 125(2):126-33. PubMed ID: 22269613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA; Nicholls SJ; Lincoff AM
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of peroxisome proliferator-activated receptor γ in simvastatin antiplatelet activity: influences on cAMP and mitogen-activated protein kinases.
    Du H; Hu H; Zheng H; Hao J; Yang J; Cui W
    Thromb Res; 2014 Jul; 134(1):111-20. PubMed ID: 24856644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety issues and prospects for future generations of PPAR modulators.
    Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P; Plutzky J
    Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleiotropic preconditioning-like cardioprotective effects of hypolipidemic drugs in acute ischemia-reperfusion in normal and hypertensive rats.
    Ravingerová T; Ledvényiová-Farkašová V; Ferko M; Barteková M; Bernátová I; Pecháňová O; Adameová A; Kolář F; Lazou A
    Can J Physiol Pharmacol; 2015 Jul; 93(7):495-503. PubMed ID: 25965412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD; Plutzky J
    Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones as antidiabetic agents: A critical review.
    Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
    Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.